Report of Foreign Issuer (6-k)
August 09 2019 - 6:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2019
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton
South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
☒
Form
40-F
☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
☐
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
☐
No
☒
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-
IMMURON LIMITED
EXPLANATORY NOTE
Immuron Limited (the “Company”) published one announcement
(the “Public Notices”) to the Australian Securities Exchange on August 8, 2019 titled:
|
-
|
“Immuron Reports Results in SAH Clinical Trial”
|
A copy of the Public Notice is attached
as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the
exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in such filing.
EXHIBITS
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
IMMURON LIMITED
|
|
|
|
|
|
|
Date: August 8, 2019
|
By:
|
/s/ Phillip Hains
|
|
|
Phillip Hains
|
|
|
Company Secretary
|
2
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Oct 2023 to Oct 2024